SNGXW (Soligenix) OCF Margin %: 0.00% (As of Mar. 2026)


SNGXW Soligenix Inc SNGXW
23 GF Score
Price $0.01
! 1 Warning Sign
View Full Analysis

What is Soligenix OCF Margin %?

Soligenix SNGXW 23 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates SNGXW with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 960 Biotechnology companies, Soligenix ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Soligenix's Cash Flow from Operations for the three months ended in Mar. 2026 was $-2.36 Mil. Soligenix's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Soligenix's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Soligenix's current OCF Yield % is -185.96%.

The historical rank and industry rank for Soligenix's OCF Margin % or its related term are showing as below:


During the past 13 years, the highest OCF Margin % of Soligenix was -47.68%. The lowest was -35575.76%. And the median was -233.52%.

SNGXW's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Soligenix OCF Margin % Related Terms

Soligenix OCF Margin % Historical Data

* Premium members only.

The historical data trend for Soligenix's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Soligenix OCF Margin % Chart

Soligenix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -35,575.76 -5,059.60 0.00 0.00 0.00

Soligenix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SNGXW
23GF Score
Soligenix Inc SNGXW
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Soligenix OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Soligenix's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-10.267/0
= %

Soligenix's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-2.358/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Soligenix (SNGXW) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Soligenix and its competitors. According to the industry distribution chart, Soligenix ranks #999999 out of 960 companies in the Biotechnology industry.
Is Soligenix's OCF Margin % too high?
Soligenix's current OCF Margin % is 0.00%. Based on the distribution chart, Soligenix ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Soligenix has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Soligenix's OCF Margin % compare to CYCN and GDTC?
According to the Biotechnology industry distribution chart, Soligenix ranks #999999 out of 960 companies for OCF Margin %. This places Soligenix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Soligenix and its competitors. Soligenix's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Soligenix stock overvalued right now?
Soligenix (SNGXW) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Soligenix's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Soligenix (SNGXW), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Soligenix Business Description

Other Exchanges SNGX:USA0A6I:UK
Address 29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
23GF Score

Get the complete analysis for SNGXW

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price